Ultragenyx Pharmaceutical's market cap is currently ―. The company's EPS TTM is $-10.116; its P/E ratio is -3.69; Ultragenyx Pharmaceutical is scheduled to report earnings on May 8, 2023, and the estimated EPS forecast is $-1.99. See an overview of income statement, balance sheet, and cash flow financials.

	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21
Income Statement	-
Total Revenue	$ 103.35M	$ 90.70M	$ 89.34M	$ 79.94M	$ 83.39M
Gross Profit	$ 98.03M	$ 82.07M	$ 81.07M	$ 73.83M	$ 79.88M
EBIT	$ -137.41M	$ -224.31M	$ -151.81M	$ -145.18M	$ -118.63M
EBITDA	$ -132.45M	$ -219.62M	$ -147.33M	$ -141.09M	$ -115.10M
Net Income Common Stockholders	$ -151.83M	$ -245.11M	$ -158.16M	$ -152.32M	$ -122.46M
Balance Sheet	-
Cash, Cash Equivalents and Short-Term Investments	$ 747.76M	$ 888.67M	$ 542.79M	$ 598.32M	$ 740.20M
Total Assets	$ 1.55B	$ 1.62B	$ 1.32B	$ 1.38B	$ 1.52B
Total Debt	$ 31.59M	$ 34.68M	$ 37.53M	$ 39.37M	$ 41.97M
Net Debt	$ -716.17M	$ -853.99M	$ -505.26M	$ -558.96M	$ -698.23M
Total Liabilities	$ 1.19B	$ 1.15B	$ 642.55M	$ 587.61M	$ 599.84M
Stockholders Equity	$ 352.49M	$ 468.83M	$ 678.07M	$ 796.42M	$ 922.56M
Cash Flow	-
Free Cash Flow	$ -117.31M	$ -121.39M	$ -108.18M	$ -179.71M	$ -70.39M
Operating Cash Flow	$ -90.34M	$ -95.34M	$ -77.26M	$ -117.52M	$ -54.34M
Investing Cash Flow	$ -171.60M	$ -161.86M	$ 79.17M	$ -37.36M	$ 69.06M
Financing Cash Flow	$ 1.88M	$ 491.88M	$ 5.84M	$ 1.61M	$ 85.72M

Currency in USD

Ultragenyx Pharmaceutical Earnings and Revenue History

Income Statement >

Ultragenyx Pharmaceutical Debt to Assets

Balance Sheet >

Ultragenyx Pharmaceutical Cash Flow

Cash Flow >

Ultragenyx Pharmaceutical Forecast EPS vs Actual EPS

Earnings >

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing